Top Philadelphia, PA Pharmaceutical Companies (44)
Don't see your company?
Create a company profile
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies.
Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality.
Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
At Verrica Pharmaceuticals, we are dedicated to easing the strain of hard-to-treat viral skin infections affecting millions of underserved patients. We are initially developing a topical therapy for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, and common warts. There is currently no FDA-approved treatment nor is there an established standard of care for either of these diseases, resulting in significant undertreated populations in two of the largest unmet needs in dermatology. Headquartered in West Chester, Pennsylvania, Verrica was founded in 2013. We are led by a seasoned management team with extensive pharmaceutical industry experience ranging from drug development through commercialization and collectively launched more than 50 products.
Pharmaceutical manufacturers, payers and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance and Exchange, enables the discovery of RWD across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy.
Amyndas is a pharmaceutical company
Enclara Pharmacia is a supplier of medications and clinical services
Medical jobs for medical experts. On-demand physician-only consulting marketplace. Source and secure physician talent within your budget.
PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market. With facilities in North America and Europe, PCI supports pharmaceutical and biotech companies with products destined for more than 100 countries around the world. PCI provides services for each stage of the product lifecycle – from early Phase I through commercial launch and long-term supply – and partners with customers to provide key insight and expertise in enabling successful commercialization and bringing lifesaving medications to patients. For more information, go to www.pci.com.
Endo Pharmaceuticals Inc., headquartered in Malvern, PA, develops and markets high-value, quality branded pharmaceutical products for patients in need. Endo Pharmaceuticals’ specialty portfolio includes products for urology, men’s health, orthopedics and endocrinology. Endo Pharmaceuticals is an operating company of Endo International plc (NASDAQ: ENDP), a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.
assisTek offers innovative electronic patient reported outcomes (ePRO), eSource, and eDiary solutions for clinical trials.
ERT is a global data and technology company.
Lannett Company, Inc. develops, manufactures and distributes generic prescription pharmaceutical products in tablet.
On Tap Pipeline is a digital marketing services provider company.
CoJourney CO. is reimagining cell and gene therapy CDMO services globally. Our platform is built on High Purity, High Yield, On Time Supply and Significantly Reduced Costs. We provide process development and clinical and commercial mfg. through a range of platform technologies, including: (1) Plasmids, (2) mRNA, (3) AAV / adenovirus, (4) Lentivirus, (5) Retrovirus, (6) Custom Viral Vectors. We have proprietary high-purity, high-yield, streamlined and cost-effective processes and our facilities are compliant under US FDA, EU EMA and China NMPA Plasmid, mRNA, and Viral Vector development, manufacturing and import/export regulations. Plasmids are manufactured in a multi-product cGMP facility that includes multiple upstream suites, downstream suites and a fill-finish suite with an isolator and filler. The facility includes 30L disposable fermenters for plasmid production. Viral Vectors are manufactured in a cGMP viral vector facility that includes multiple upstream cell culture, upstream viral vector production suites, downstream processing and fill-finish suites. The facility includes 500L and 2,000L disposable bioreactors for viral vector production. CoJourney’s Process Development labs allow separate, client specific project rooms and are equipped with state of the art and large-scale equipment. The analytical development and Quality Control laboratories provide state of the art analytical equipment are focused on analytical development and performing all stages of release testing for plasmids and viral vectors. CoJourney is currently manufacturing AAV-based gene therapies that have been approved for use in global clinical trials: 1) rAAV based gene therapy for Neurovascular Age-Related Macular Degeneration (wet AMD) in USA 2) AAV based gene therapy for Spinal Muscular Atrophy (SMA) in China Please contact us to discuss how our innovative approaches and timely, cost-effective solutions can address your needs. Please contact us for more information.
http://www.jdptherapeutics.com
Work Your Passion. Live Your Purpose.
